HOLLISTON, Mass., July 18, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2017 after market trading hours on Thursday, July 27, 2017. A conference call to discuss the company's second quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 45318167.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through August 3, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



